` SDGR (Schrodinger Inc) vs S&P 500 Comparison - Alpha Spread

SDGR
vs
S&P 500

Over the past 12 months, SDGR has underperformed S&P 500, delivering a return of 3% compared to the S&P 500's 12% growth.

Stocks Performance
SDGR vs S&P 500

Loading

Performance Gap
SDGR vs S&P 500

Loading
SDGR
S&P 500
Difference

Performance By Year
SDGR vs S&P 500

Loading
SDGR
S&P 500
Add Stock

Competitors Performance
Schrodinger Inc vs Peers

S&P 500
SDGR
VEEV
PME
DOCS
2413
Add Stock

Schrodinger Inc
Glance View

Market Cap
1.7B USD
Industry
Health Care

In the bustling realm of computational chemistry, Schrödinger Inc. has carved a unique niche, transforming the way pharmaceutical and biotechnology companies approach drug discovery. Founded in 1990, the company has become synonymous with innovation, leveraging powerful physics-based software platforms that simulate molecular interactions at an atomic level. By providing researchers with tools to predict the behavior of complex biological systems, Schrödinger effectively bridges the gap between traditional experimental methods and cutting-edge computational techniques. Their flagship product, the Schrödinger platform, is instrumental in accelerating the drug discovery process, allowing scientists to virtually test countless compounds before selecting the most promising candidates for laboratory synthesis and testing. This capability significantly reduces the time and cost involved in bringing new drugs to market, providing tremendous value to its clients in the pharmaceutical industry. Schrödinger's financial success stems from its diversified business model, which includes software licensing, collaborative research and development projects, and, interestingly, strategic investments in biotech firms. The company licenses its software to a broad range of industries, from pharmaceuticals to materials science, generating a steady stream of revenue. Meanwhile, their collaborative projects enable Schrödinger to participate in revenue sharing or milestone payments based on the compounds developed using their technology. Additionally, by investing in biotech companies utilizing their software, Schrödinger not only fosters innovation but also stands to gain financially from any commercial success. This multifaceted approach not only secures their leadership in the industry but also ensures a robust growth trajectory, as they continue to expand the horizons of computational science.

SDGR Intrinsic Value
16.35 USD
Overvaluation 30%
Intrinsic Value
Price
Back to Top